Citadel Advisors
LUMO

Citadel Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Citadel Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,900
Closed -$66K – 10327
2019
Q4 		$66K Sell
2,900
-1,156
-29% -$16.5K ﹤0.01% 8684
2019
Q3 		$58K Buy
4,056
+1,534
+61% +$22.5K ﹤0.01% 8664
2019
Q2 		$34K Buy
+2,522
New +$38.1K ﹤0.01% 8840
2019
Q1 		– Sell
-1,956
Closed -$27K – 9997
2018
Q4 		$27K Sell
1,956
-2,677
-58% -$47.1K ﹤0.01% 8656
2018
Q3 		$100K Sell
4,633
-3,823
-45% -$116K ﹤0.01% 8581
2018
Q2 		$362K Buy
8,456
+1,400
+20% +$64.1K ﹤0.01% 6902
2018
Q1 		$460K Buy
7,056
+4,534
+180% +$321K ﹤0.01% 6020
2017
Q4 		$184K Sell
2,522
-845
-25% -$69.9K ﹤0.01% 7170
2017
Q3 		$308K Buy
3,367
+1,556
+86% +$119K ﹤0.01% 6033
2017
Q2 		$120K Sell
1,811
-1,222
-40% -$151K ﹤0.01% 6840
2017
Q1 		$658K Buy
3,033
+144
+5% +$20.6K ﹤0.01% 4606
2016
Q4 		$267K Sell
2,889
-2,689
-48% -$303K ﹤0.01% 5843
2016
Q3 		$754K Sell
5,578
-1,278
-19% -$127K ﹤0.01% 4220
2016
Q2 		$695K Buy
6,856
+2,578
+60% +$320K ﹤0.01% 4043
2016
Q1 		$701K Buy
4,278
+1,700
+66% +$345K ﹤0.01% 3930
2015
Q4 		$844K Sell
2,578
-289
-10% -$94.1K ﹤0.01% 3788
2015
Q3 		$925K Sell
2,867
-2,600
-48% -$1.14M ﹤0.01% 3920
2015
Q2 		$2.18M Buy
5,467
+1,711
+46% +$727K ﹤0.01% 2971
2015
Q1 		$1.85M Buy
3,756
+278
+8% +$108K ﹤0.01% 3161
2014
Q4 		$1.24M Sell
3,478
-2,066
-37% -$615K ﹤0.01% 3491
2014
Q3 		$1.07M Buy
5,544
+2,977
+116% +$655K ﹤0.01% 3628
2014
Q2 		$613K Sell
2,567
-333
-11% -$67.7K ﹤0.01% 4127
2014
Q1 		$741K Buy
2,900
+711
+32% +$217K ﹤0.01% 3815
2013
Q4 		$434K Sell
2,189
-1,011
-32% -$180K ﹤0.01% 4185
2013
Q3 		$541K Buy
+3,200
New +$515K ﹤0.01% 3726

Other funds holding LUMO

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citadel Advisors's LUMO Position: Q3 2024 in Review

Citadel Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2024, closing a stake of 18,745 shares — an estimated $43.5K sold.

Citadel Advisors first reported a position in LUMO in Q4 2013 and held it in 26 quarters. The position peaked at $5.26M in Q1 2015. 28 funds tracked by Wall St. Rank hold LUMO as of Q3 2024.

  • Citadel Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 18,745 Lumos Pharma, Inc. Common Stock shares in Q3 2024, an estimated $43.5K.
  • Citadel Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 26 quarters.
  • Citadel Advisors's Lumos Pharma, Inc. Common Stock position peaked at $5.26M in Q1 2015.
  • 28 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.